Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells

被引：0
|
作者：
Feifei Xu
Fengliang Wang
Ting Yang
Yuan Sheng
Ting Zhong
Yun Chen
机构：
[1] Nanjing Medical University,School of Pharmacy
[2] Nanjing Maternity and Child Health Care Hospital,undefined
来源：
Cancer Cell International | / 14卷
关键词：
Multi-drug Resistance Acquisition (MDR); P-glycoprotein (P-gp); Drug-specific; Doxorubicin (DOX); Paclitaxel (PTX);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] The Breast Cancer Stem Cells Traits and Drug Resistance
    Zheng, Qinghui
    Zhang, Mengdi
    Zhou, Fangfang
    Zhang, Long
    Meng, Xuli
    FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [42] A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells
    Zhenfeng Duan
    Jianming Zhang
    Shunan Ye
    Jacson Shen
    Edwin Choy
    Gregory Cote
    David Harmon
    Henry Mankin
    Yingqi Hua
    Yu Zhang
    Nathanael S Gray
    Francis J Hornicek
    BMC Cancer, 14
  • [43] A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells
    Duan, Zhenfeng
    Zhang, Jianming
    Ye, Shunan
    Shen, Jacson
    Choy, Edwin
    Cote, Gregory
    Harmon, David
    Mankin, Henry
    Hua, Yingqi
    Zhang, Yu
    Gray, Nathanael S.
    Hornicek, Francis J.
    BMC CANCER, 2014, 14
  • [44] Penetration characteristics of paclitaxel and doxorubicin in multilayers of cancer cells
    Lee, Joo-Ho
    Al-Abd, Ahmed M.
    Kang, Choon-Mo
    Kuh, Hyo-Jeong
    DRUG METABOLISM REVIEWS, 2006, 38 : 90 - 91
  • [45] Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer
    Schwonzen, M
    Kurbacher, CM
    Mallmann, P
    ANTI-CANCER DRUGS, 2000, 11 (09) : 681 - 685
  • [46] Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
    Gehl, J
    Boesgaard, M
    Paaske, T
    Jensen, BV
    Dombernowsky, P
    ANNALS OF ONCOLOGY, 1996, 7 (07) : 687 - 693
  • [47] Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin
    Cheryl A Sherman-Baust
    Kevin G Becker
    William H Wood III
    Yongqing Zhang
    Patrice J Morin
    Journal of Ovarian Research, 4
  • [48] Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin
    Sherman-Baust, Cheryl A.
    Becker, Kevin G.
    Wood, William H.
    Zhang, Yongqing
    Morin, Patrice J.
    JOURNAL OF OVARIAN RESEARCH, 2011, 4
  • [49] Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells
    Sivakumar Vijayaraghavalu
    Vinod Labhasetwar
    Drug Delivery and Translational Research, 2018, 8 : 1289 - 1299
  • [50] Co-encapsulated resveratrol and paclitaxel in liposomes for drug resistance reversal in breast cancer
    Yang, X.
    Meng, J.
    FEBS OPEN BIO, 2019, 9 : 382 - 382
12345